Skip to main content
SpringerLink
Log in

How Much is the Cost of Visual Impairment

Caveat Emptor

  • Commentary
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Lafuma A, Brézin A, Lopatriello S, et al. Evaluation of nonmedical costs associated with visual impairment in four European countries: France, Italy, Germany and the UK. Pharmacoeconomics 2006; 24 (2): 193–205

    Article  PubMed  Google Scholar 

  2. Meads C, Salas C, Roberts T, et al. Clinical effectiveness and cost utility of photodynamic therapy for wet age-related macular degeneration: a systematic review and economic evaluation. Health Technol Assess 2003; 7 (9): 1–98

    Google Scholar 

  3. Wright SE, Keeffe JE, Thies LS. Direct costs of blindness in Australia. Clin Experiment Ophthalrnol 2000; 28: 140–142

    Article  CAS  Google Scholar 

  4. Bonastre J, Le Pen C, Soubrane G, et al. The burden of agerelated macular degeneration. Pharmacoeconomics 2003; 21 (3), 181–190

    Article  PubMed  Google Scholar 

  5. Ethical Strategies Ltd. The costs of blindness: an analysis of the costs of visual impairment and blindness in the United Kingdom. Reading: Guide Dogs for the Blind Association, 2003

    Google Scholar 

  6. Department of Health. Registered blind and partially sighted people year ending 31 March 2003. London: Office for National Statistics, 2003

  7. Miners AH, Garau M, Fidan D, et al. Comparing estimates of cost effectiveness submitted to the National Institute for Clinical Excellence (NICE) by different organisations: retrospective study. BMJ 2005; 330 (7482): 65–68

    Article  PubMed  CAS  Google Scholar 

  8. Burton B, Rowell A. Unhealthy spin. BMJ 2003; 326: 1205–1207

    Article  PubMed  Google Scholar 

  9. Alcon Incorporated. Protocol C-02-60 information for potential participants about a phase III clinical trial to evaluate an investigational treatment for stopping the progression of dry AMD to wet AMD [online]. Available from URL: http://www.alconlabs.comlus/eo/clinicalstudies/ [Accessed 2005 Feb 21]

  10. National Institute for Clinical Excellence. Guide to the technology appraisal process. London: NICE, 2004

    Google Scholar 

  11. National Institute for Clinical Excellence. Guidance on the use of photodynamic therapy for age-related macular degeneration. London: NICE, 2004

    Google Scholar 

  12. Hill R, Bagust A, Bakhai A, et al. Coronary artery stents: a rapid systematic review and economic evaluation. Health Technol Assess 2004; 8 (35): 1–242

    Google Scholar 

  13. Meads C, Hyde C. What is the cost of blindness? Br J Ophthalmol 2003; 87: 1201–1204

    Article  PubMed  CAS  Google Scholar 

  14. Raftery J. NICE: faster access to modern treatments? Analysis of guidance on health technologies. BMJ 2001; 323: 1300–1303

    Article  PubMed  CAS  Google Scholar 

  15. Burls A, Sandercock J. How to make a compelling submission to NICE: tips for sponsoring organisations. BMJ 2003; 327: 1446–1448

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this commentary. The authors have no conflicts of interest that are directly relevant to the content of this commentary.

Author information

Authors and Affiliations

  1. Department of Public Health and Epidemiology, University of Birmingham, Edgbaston, Birmingham, B15 2TT, England

    Catherine Meads & Chris Hyde

Authors
  1. Catherine Meads
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chris Hyde
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Catherine Meads.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Meads, C., Hyde, C. How Much is the Cost of Visual Impairment. Pharmacoeconomics 24, 207–209 (2006). https://doi.org/10.2165/00019053-200624020-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200624020-00008

Keywords

Search

Navigation